Insmed Incorporated

INSM

US4576693075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-17 pm EDT			5-day change	1st Jan Change
100.28 ^USD	-1.29%		+41.88%	+45.25%

Jun. 12	Insmed Insider Sold Shares Worth $5,148,024, According to a Recent SEC Filing	MT
Jun. 12	Insmed Prices $750 Million Common Stock Offering	MT

Insmed Announces Positive Topline Results From Phase 2B Study Of Its Blood Pressure Drug

Published on 06/10/2025 at 07:15

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Insmed Incorporated

Insmed Insider Sold Shares Worth $5,148,024, According to a Recent SEC Filing	Jun. 12	MT
Insmed Prices $750 Million Common Stock Offering	Jun. 12	MT
Insmed Announces Pricing Of $750 Million Public Offering Of Common Stock At $96 Per Share	Jun. 11	RE
Insmed Plans $650 Million Public Offering	Jun. 11	MT
Insmed Incorporated Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 09:20 AM	Jun. 11
BofA Securities Raises Insmed Price Target to $109 From $94, Maintains Buy Rating	Jun. 11	MT
BofA Securities Raises Insmed Price Target to $109 From $94, Maintains Buy Rating	Jun. 11	MT
CPI Relief Sparks Wall Street Optimism	Jun. 11
RBC Raises Price Target on Insmed to $106 From $99, Keeps Outperform Rating	Jun. 11	MT
Morgan Stanley Raises Price Target on Insmed to $102 From $90, Keeps Overweight Rating	Jun. 11	MT
Mizuho Raises Price Target on Insmed to $110 From $96, Keeps Outperform Rating	Jun. 11	MT
Analyst recommendations: Arista Networks, Etsy, Micron Technology, Docusign, Gitlab…	Jun. 11
Equity Markets Close Higher After US-China Trade Talks Stretch Over Second Day	Jun. 10	MT
Sector Update: Health Care Stocks Rise Late Afternoon	Jun. 10	MT
Sector Update: Health Care Stocks Higher Tuesday Afternoon	Jun. 10	MT
Insmed Incorporated - Special Call	Jun. 10
Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints	Jun. 10	MT
Insmed's drug for rare lung disease achieves 'home run' in mid-stage trial	Jun. 10	RE
Wall Street mixed as US-China trade talks grab focus	Jun. 10	RE
Insmed Incorporated Announces Positive Topline Results from Phase 2B Study of Treprostinil Palmitil Inhalation Powder as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension	Jun. 10	CI
Liquidia, United Therapeutics Shares Fall Pre-Bell After Rival Insmed's Phase 2b PAH Trial Meets Endpoints	Jun. 10	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	Jun. 10	MT
Wall St set to open slightly higher as US-China trade talks grab focus	Jun. 10	RE
Sector Update: Health Care	Jun. 10	MT
Insmed Shares Rise on Positive Results From Study of Treatment for High Blood Pressure in Lungs	Jun. 10	DJ

Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

Employees

1,271

Sector

Biotechnology & Medical Research

Calendar

Jul. 30 - Q2 2025 Earnings Release (Projected)

More about the company